Objective To investigate the clinical efficacy of Qili Qiangxin capsule combined with dapagliflozin in the treat-ment of newly developing heart failure after acute myocardial infarction.Methods Seventy-four patients with newly developing heart failure after acute myocardial infarction admitted to Lujiang County People's Hospital from May 2022 to September 2023 were selected as the research subjects and divided into two groups using a random number table method,with 37 in each group.The patients in the control group were given dapagliflozin while those in the study group were given Qili Qiangxin capsule in addition to dapagliflozin.Then the clinical efficacy,inflammatory factors,apolipoprotein levels,and cardiac enzyme index were compared between the two groups.Results After treatment,the study group reported a higher clinical efficacy rate as compared with the control(91.89%vs 72.97%,χ2=4.573,P＜0.05).The levels of hs-CRP and interleukin-6 decreased in both groups and they were significantly lower in the study group than in the control((9.18±1.40)mg·L-1 vs(13.96±2.13)mg·L-1,(17.33±4.21)ng·L-1 vs(21.48±4.95)ng·L-1,t=3.885,11.407,both P＜0.05).Compared with before treatment,both groups showed an increase in apolipoprotein A1 and a decrease in apolipoprotein B after treatment.After treat-ment,the level of apolipoprotein A1 in the study group was higher than that in the control group((1.89±0.24)g·L-1 vs(1.15±0.21)g·L-1),and the level of apolipoprotein B was lower than that in the control group((1.08±0.23)g·L-1 vs(1.25±0.28)g·L-1),(t=14.115,2.854,both P＜0.05).A reduction in serum concentrations of creatine kinase and creatine kinase isoenzyme-MB was detected in all patients after treatment,and it was remarkably lower in the study group than in the control((61.34±6.15)U·L-1 vs(84.09±7.52)U·L-1,(25.38±3.06)U·L-1 vs(33.41±4.45)U·L-1,t=14.245,9.044,both P＜0.05).Conclusion Application of Qili Qiangxin capsule combined with dapagli-flozin in the treatment of newly developing heart failure after acute myocardial infarction can effectively attenuate the inflammation response,regulate apolipoprotein expression,improve cardiac function,reduce damage to myocardial tissue and promote effective rate.
Qili Qiangxin capsuleDapagliflozinAcute myocardial infarctionHeart failureCardiac function
万方数据
维普
